Creative Planning acquired a new stake in shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,037 shares of the company’s stock, valued at approximately $105,000. Creative Planning owned approximately 0.05% of Fennec Pharmaceuticals as of its most recent SEC filing.
Separately, Opaleye Management Inc. boosted its position in Fennec Pharmaceuticals by 3.1% in the first quarter. Opaleye Management Inc. now owns 873,000 shares of the company’s stock worth $10,559,000 after purchasing an additional 26,100 shares during the last quarter. Institutional investors and hedge funds own 49.78% of the company’s stock.
NASDAQ FENC traded down $0.39 during trading on Friday, reaching $9.52. The company’s stock had a trading volume of 159,800 shares, compared to its average volume of 76,876. The firm has a market capitalization of $183.84 million, a P/E ratio of -19.91 and a beta of -0.36. Fennec Pharmaceuticals Inc has a one year low of $7.55 and a one year high of $14.99.
Several research firms have weighed in on FENC. HC Wainwright set a $18.00 price objective on Fennec Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, August 7th. Zacks Investment Research cut Fennec Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 24th. Finally, ValuEngine raised Fennec Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, May 17th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $17.00.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
Featured Article: Fundamental Analysis and Choosing Stocks
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.